ema glp-1 vision loss recommendation ophthalmology november 2025 Warns of Risk from Semaglutide As GLP-1 medications continue to

Historically, OSA treatment has relied heavily on mechanical interventions, such as Continuous Positive Airway Pressure (CPAP) devices

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone

Setting realistic expectations prevents discouragement during the initial phase when progress may not yet be visible

Quick Note: Participants reported a daily food intake of 1500 to 1600 kcal, which is typical of a weight loss diet

This is a new, practical safety concern that surgical societies are rushing to address

For example, altered levels of short-chain ACs, including C2 and C3, have been observed in coronary artery disease and diabetes [6, 55]